Navigation Links
Keryx Biopharmaceuticals' Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
Date:9/14/2009

tients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available athttp://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
        Lauren Fischer
        Director, Investor Relations
        Keryx Biopharmaceuticals, Inc.
        Tel: 212.531.5962
        E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pomerantz LLP is investigating claims on behalf ... "Company") (NASDAQ: VTAE ).  Such investors are ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... officers and/or directors have violated Sections 10(b) and 20(a) ... On February 27, 2015, the Company announced that ...
(Date:2/27/2015)... Securities lawyers at Dunnam & Dunnam ... (NASDAQ: SLXP ) in connection with a ... are encouraged to contact attorney Hamilton Lindley by ... upon the shareholder value of the transaction. Under terms ... $158.00 per share in cash. At least one analyst ...
(Date:2/27/2015)... , February 27, 2015 Report ... study showing you trends, R&D progress, and predicted revenues ... heading? What are the commercial prospects for this market ... potential revenues and other trends to 2025, discussing data, ... lets you assess regenerative medicine : cell-based therapies ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
(Date:2/28/2015)... 2015 Memphis, TN: MedixSafe has retracted ... a new security reader named Guardian 2. The ... a new biometric scanner that significantly increases the ... the new biometric scanner provides fast and easy ... MedixSafe narcotics lockers with Vanguard technology ...
(Date:2/28/2015)... Angeles, California (PRWEB) February 28, 2015 ... fully supported and showcased emerging brand at Houston ... held in Las Vegas sending its executive delegates ... Director of Business Development and Training Randolph Clarito. ... Association (IFA), was held last February 4-7 and ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 ... Devices (IPD), has introduced miniature, wire bondable, silicon ESD ... Power LED markets. The ESD88NP and ... currents away from sensitive LED and IC products. ... Multilayer Varistors (MLV). All devices meet the requirements ...
(Date:2/27/2015)... 2015 Those who self-injure, ... misunderstood, misdiagnosed and therefore aren’t receiving effective ... Jacksonville-based addiction treatment center Lakeview Health ... acclaimed Lakeview Professional Lecture Series to counselors, ... this complicated condition. , “Self-injurious ...
(Date:2/27/2015)... Clinovo, a leading provider of cloud-based eClinical software, ... at the CALBIO2015 conference taking place in ... at Booth # 141. , ClinCapture ... builder allowing Clinical Trials Managers to create CRFs and ... programming experience. Clinovo’s new pricing model offers a free ...
Breaking Medicine News(10 mins):Health News:New Name Announced For Newest MedixSafe Readers – MedixSafe Vanguard 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:Clinovo to Demo Its Self-Service, Cloud-Based EDC Solution at CALBIO2015 on March 2nd and 3rd, 2015 2
... Germany has spawned a major scientific debate by claiming ... the atmosphere every year exacerbating the greenhouse effect. ... Planck Institute for Chemistry has reaffirmed findings by his ... had detected methane exhaled from living plants. ...
... unfairly not only makes your blood boil in anger, but as ... of having a heart attack. ,Researchers base their ... British government in London. ,As a part of the ... responses to the statement: "I often have the feeling that I ...
... the horizontally inclined. An American inventor has come out ... lose weight , while working at the computer. ... who designed the standup "walk-and-work" desk, suggest it could ... are traditionally sit-down tasks. The workstation can be locked ...
... States, anxiety appears to increase the risk of heart attacks and ... ,Coronary artery disease is caused by plaque build-up on the inside ... heart. This causes them to harden and narrow. ... and other serious complications. , According to a report ...
... from grains and cereals and of magnesium may each be ... to a report and meta-analysis in the issue of ... number of people diagnosed with diabetes worldwide may increase from ... to background information in the article. The associated illness, death ...
... In a recent survey, scientists have identified 216 compounds in ... ,The most inclusive survey till date of environmental chemicals linked ... are frequently experienced by most women. ,The extensive ... a long list of chemicals in our food, air and ...
Cached Medicine News:Health News:Scientists Saying Against Trees Sparks Debate 2Health News:Heart Attack Risk Increased by Unfair Treatment 2Health News:Stand Up And Get Back To Work! 2Health News:Dont Worry- Be Good To Your Heart 2Health News:Risk of Diabetes is Reduced by Intake of Grain Fiber and Magnesium 2Health News:List of Compounds That Causes Breast Cancer Identified 2
... WarmAir® system from CSZ safely provides effective ... of the unique patented design of our ... lower velocity blower which supplies gently moving, ... that may spread contaminants to your patient ...
Since 1964, in its plants of Sesto Fiorentino, Sbisà produces a wide and qualified range of instruments for ophthalmology and optometry....
Inquire...
Inquire...
Medicine Products: